1. World Cancer Report. International Agency for research on Cancer. 2008Retrieved 2011-02-26.
2. Beckmann MW, Bani MR, Fasching PA, Strick R and Lux MP. Risk and risk assessment for breast cancer: molecular and clinical aspects. Maturitas 2007.20; 57(1): 56-60.
3.Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, Ebrahimi M. Breast cancer in Iran: an epidemiological review. Breast J 2007; 13(4):383-91.
4. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005; 123(4): 541-6.
5. Blanco G, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P. Prognostic factors in recurrent breast cancer: relationship to site of recurrence, disease- free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 1990; 62(1): 142-6.
6. Marzec KA, Baxter R C, and. Martin JL. Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer. BoiMed Res Int 2015; 2015:638526.
8. Herr DR, Chun J. Effects of LPA and S1P on the nervous system and implications for their involvement in disease.
Curr Drug Targets2007;8 (1):155-67.
10. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 2008 Aug; 9(8):662-73.
13. Alshaker H, Sauer L, Monteil D, Ottavini S, Strivats S, Bohler T, Pchejetshki D. Therapeutic potential of targeting SK1 in human cancers.
Adv Cancer Res 2013; 117:143-200.
14. Zheng XD, Zhang Y, Qi XW, Wang MH, Sun P, Zhang Y, et al. Role of Sphk1 in the malignant transformation of breast epithelial cells and breast cancer progression.
Indian J Cancer 2014 Oct-Dec; 51(4):524-9.
16. Ko P, Kim D, You E, Jung J, Oh S, Kim J et al. Extracellular Matrix Rigidity-dependent Sphingosine-1-phosphate Secretion Regulates Metastatic Cancer Cell Invasion and Adhesion.
Sci Rep 2016 Feb 15; 6:21564.
17. Tian H, Yu Z. Resveratrol induces apoptosis of leukemia cell line K562 by modulation of sphingosine kinase-1 pathway.
Int J Clin Exp Phathol 2015 Mar 1; 8(3):2755-62.
18. Salama MF, Carroll B, Adada M, PuLkoski-Gross M, Hannun YA, Obeid LM. A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.
FASEB J 2015 Jul; 29(7):2803-13.
19. Beach JA, Aspuria PJ, Cheon DJ, Lawenson K, Agadjanian H, Walsh CS. Sphingosine kinase 1 is required for TGF-β mediated fibroblastto- myofibroblast differentiation in ovarian cancer.
Oncotarget 2016 Jan 26; 7(4):4167-82.
21. Zhao R, Milstien S, Zhou H, Spiegel S, Takabe K: Sphingosine-1-phosphateproduced by sphingosine kinase 1 promotes breast cancer progressionby stimulating angiogenesis and lymphangiogenesis. Cancer Res 2012 Feb 1; 72(3):726–735.
23. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression.Net Rev Cancer 2009 Feb; 9(2):108-22.
24. Leventl KR, Yu H, Kass L, Lakins JN, Egeblad M, ErlerJT, Fong SF et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. cell 2009 Nov 25;139(5):891-906..
25. Shirai K, Kaneshiro T, Wada M, Furuya H, Bielawski J, Hannun YA, Obeid LM, et al. A role of sphingosine kinase 1 in head & neck carcinogenesis.
Cancer Prev Res (Phila). 2011 Mar; 4(3):454-62.
28. Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R et al. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells.
Mol Cell Biol 2010 Aug; 30(15):3827-41.
29. Pyne NJ, Tonelli F, Lim KG, Long J, Edwards J, Pyne S: Targeting sphingosine kinase 1 in cancer. AdvBiolRegul 2012 Jan; 52:31–38.
30. Ohotski J, Long JS, Orange C, Elsberger B, Mallon E, Doughty J.Expression of sphingosine 1-phosphate receptor4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br J Cancer 2012; Apr 10; 106(8):1453-9.
32. Alshker H, Krell J, Frampton AE, Waxman J, BlyussO,Zaikin A. et al. Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway. Breast Cancer Res 2014 Oct 25; 16(5):426.
34. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance ofsphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008 Nov; 112(1):41–52.
35. Blachnio-Zabielska AU, Pulka M, Baranowski M, Nikolajuk A, ZabielskiP,Gorska M. Ceramide metabolism is affected by obesity and diabetes in human adipose tissue.
J Cell Physiol 2012 Feb; 227(2):550-7.
42. Sobue S, Lwasiki T, Suqisaki C, Nagatu K, Kikuchi R, Murakami M. QuantitativeRT-PCRanalysis of sphingolipid metabolic enzymes in acuteleukemia and myelodysplastic syndromes. Leukemia 2006 Nov; 20(11):2042-6.
43. Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA, et al. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue.
J Histochem Cytochem 2005 Sep; 53(9):1159-66.